Peramivir Trihydrate

Catalog No.S2716 Synonyms: BCX-1812, RWJ-270201, S-021812

For research use only.

Peramivir Trihydrate (BCX-1812, RWJ-270201, S-021812) is a trihydrate of the anti-infection agent peramivir which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.

Peramivir Trihydrate Chemical Structure

CAS No. 1041434-82-5

Selleck's Peramivir Trihydrate has been cited by 2 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Neuraminidase Inhibitors

Biological Activity

Description Peramivir Trihydrate (BCX-1812, RWJ-270201, S-021812) is a trihydrate of the anti-infection agent peramivir which is a transition-state analogue and a potent, specific influenza viral neuraminidase inhibitor with an IC50 of median 0.09 nM.
In vivo Peramivir protects mice against severe disease outcomes following infection with highly pathogenic avian influenza and multi-dose treatment was efficacious in ferrets. [1] Peramivir combined with Oseltamivir perform better than suboptimal doses of each compound alone to treat influenza infections in mice. [2] Peramivir (30 mg/kg) is effective in promoting the survival of mice infected with systemically replicating H5N1 virus. [3] Peramivir is 30% protective against H1N1 virus in mice at 0.5 mg/kg/d, but ineffective at lower doses when used as monotherapy. Peramivir combined with favipiravir increases the numbers of survivors by 10-50% when the 0.025 mg/kg/d, 0.05 mg/kg/d, and 0.1 mg/kg/d doses of Peramivir are combined with 20 mg/kg/d Favipiravir and when all doses of Peramivir are combined with 40 mg/kg/d Favipiravir. Peramivir combined with favipiravir results in an increase in lifespan, improved body weight and significant reductions in lung hemorrhage score and lung weight in H1N1 infected mice. [4] Peramivir (1 mg/kg/d) combined with Rimantadine (5 mg/kg/d and 10 mg/kg/d) produces weight losses of 1.69 and 0.69, respectively, whereas the combination of 3.0 mg/kg/d Peramivir with 10 and 30 mg/kg/d Rimantadine does not show any weight loss in sub-lethal influenza A (H3N2) virus mouse model. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 0.2 mg/mL
(0.52 mM)
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 382.45
Formula

C15H28N4O4.3H2O

CAS No. 1041434-82-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CCC(CC)C(C1C(CC(C1O)C(=O)O)N=C(N)N)NC(=O)C.O.O.O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02635724 Completed Drug: Peramivir Influenza BioCryst Pharmaceuticals December 2015 Phase 3
NCT02369159 Completed Drug: Peramivir|Drug: Oseltamivir Influenza BioCryst Pharmaceuticals March 11 2015 Phase 3
NCT01224795 Terminated Drug: Peramivir|Drug: Placebo Comparator Influenza BioCryst Pharmaceuticals|Department of Health and Human Services October 2010 Phase 3
NCT01146353 Withdrawn -- Influenza|Renal Failure Midwestern University|Northwestern University|BioCryst Pharmaceuticals February 2010 --
NCT01063933 Withdrawn Drug: Peramivir Influenza National Institute of Allergy and Infectious Diseases (NIAID) Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Peramivir Trihydrate | Peramivir Trihydrate supplier | purchase Peramivir Trihydrate | Peramivir Trihydrate cost | Peramivir Trihydrate manufacturer | order Peramivir Trihydrate | Peramivir Trihydrate distributor